(Q24242150)

2

0 references

Fabio Brusaferri

3

0 references

Ian Galea

4

0 references

Alessandra Protti

5

0 references

Chiara Spreafico

Cochrane Database of Systematic Reviews

6

0 references

language of work or name

English

0 references

publication date

23 January 2008

0 references

published in

0 references

issue

1

0 references

page(s)

CD006264

0 references

cites work

Steroids and brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

A serial study of new MS lesions and the white matter from which they arise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Mitoxantrone for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Diagnosis and classification of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Corticosteroids treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Current approved options for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Other therapy options and future strategies for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

USE OF AN ORAL CORTICOSTEROID IN THE TREATMENT OF MULTIPLE SCLEROSIS; A DOUBLE-BLIND STUDY

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

The optic neuritis treatment trial: three-year follow-up results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006264.PUB2

7 January 2021

10.1002/14651858.CD006264.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2882172

2882172

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference